Final results from two multi-center, Phase 3b, double-blind, parallel group studies will be presented, including a comparison of daily dosing of RADICAVA ORS (edaravone) with the FDA-approved on ...
This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other ...
JERSEY CITY, N.J., Dec. 4, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of two abstracts on investigational ND0612 in Parkinson's disease (PD ...
The Japanese pharma company files complaint against Lupin Pharmaceuticals | Suit alleges patent infringement over the company ...
Mitsubishi Tanabe Pharma Corp. has identified serine/threonine-protein salt-inducible kinases (SIK) inhibitors reported to be useful for the treatment of psoriatic arthritis, lupus nephritis, ...
Hosted on MSN26d
Blackstone, Bain to bid for Mitsubishi pharma unit in up to $3.5 billion deal, sources sayHONG KONG (Reuters) - Global private equity firms Blackstone and Bain Capital are among final bidders for Mitsubishi Tanabe Pharma, a unit of Japan's Mitsubishi Chemical Group, in a deal that ...
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800 ...
HONG KONG, Dec 13 (Reuters) - Global private equity firms Blackstone (BX.N), opens new tab and Bain Capital are among final bidders for Mitsubishi Tanabe Pharma, a unit of Japan's Mitsubishi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback